Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics.

anthropology ethnography extrapharmacological variables hallucinogens history morality and values psychedelics psychotherapy

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2021
Historique:
received: 31 03 2021
accepted: 09 06 2021
entrez: 19 8 2021
pubmed: 20 8 2021
medline: 20 8 2021
Statut: epublish

Résumé

The revival of psychedelic research coincided and more recently conjoined with psychopharmacological research on how drugs affect moral judgments and behaviors. This article makes the case for a moral psychopharmacology of psychedelics that examines whether psychedelics serve as non-specific amplifiers that enable subjects to (re-)connect with their values, or whether they promote specific moral-political orientations such as liberal and anti-authoritarian views, as recent psychopharmacological studies suggest. This question gains urgency from the fact that the return of psychedelics from counterculture and underground laboratories to mainstream science and society has been accompanied by a diversification of their users and uses. We propose bringing the pharmacological and neuroscientific literature into a conversation with historical and anthropological scholarship documenting the full spectrum of moral and political views associated with the uses of psychedelics. This paper sheds new light on the cultural plasticity of drug action and has implications for the design of psychedelic pharmacopsychotherapies. It also raises the question of whether other classes of psychoactive drugs have an equally rich moral and political life.

Identifiants

pubmed: 34408677
doi: 10.3389/fpsyt.2021.680064
pmc: PMC8365088
doi:

Types de publication

Journal Article

Langues

eng

Pagination

680064

Informations de copyright

Copyright © 2021 Langlitz, Dyck, Scheidegger and Repantis.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

N Engl J Med. 2021 Apr 15;384(15):1402-1411
pubmed: 33852780
J Relig Health. 1966 Jul;5(3):175-208
pubmed: 24424798
ACS Pharmacol Transl Sci. 2020 Dec 16;4(2):578-581
pubmed: 33860187
Curr Biol. 2017 Feb 6;27(3):451-457
pubmed: 28132813
AMA Arch Gen Psychiatry. 1959 Jul;1:58-69
pubmed: 13842570
Neuroethics. 2017;10(3):363-373
pubmed: 28890738
J Psychoactive Drugs. 2017 Jul-Aug;49(3):182-191
pubmed: 28443703
J Psychopharmacol. 2018 Jul;32(7):725-731
pubmed: 29446697
J Psychopharmacol. 2016 Dec;30(12):1259-1267
pubmed: 27852960
Curr Biol. 2012 May 22;22(10):922-6
pubmed: 22578420
Psychopharmacology (Berl). 2021 Jul;238(7):1899-1910
pubmed: 33694031
J Psychopharmacol. 2015 Jun;29(6):661-8
pubmed: 25735993
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2338-2346
pubmed: 31964815
J Med Ethics. 2020 May 27;:
pubmed: 32461241
Account Res. 2013;20(1):27-41
pubmed: 23281583
ACS Pharmacol Transl Sci. 2020 Dec 10;4(2):568-572
pubmed: 33861219
J Med Ethics. 2020 Nov 4;:
pubmed: 33148774
J Psychopharmacol. 2018 Jul;32(7):756-769
pubmed: 29938565
Psychopharmacology (Berl). 2015 Feb;232(4):785-94
pubmed: 25242255
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1262-6
pubmed: 21220339
J Psychopharmacol. 2017 Aug;31(8):975-988
pubmed: 28631526
Science. 2008 Jun 27;320(5884):1739
pubmed: 18535210
Nature. 2005 Jun 2;435(7042):673-6
pubmed: 15931222
Prog Brain Res. 2009;178:287-304
pubmed: 19874977
Psychopharmacology (Berl). 2018 Feb;235(2):547-550
pubmed: 28795211
Front Psychiatry. 2019 Dec 03;10:881
pubmed: 31849730

Auteurs

Nicolas Langlitz (N)

Department of Anthropology, The New School for Social Research, New York, NY, United States.

Erika Dyck (E)

Department of History, University of Saskatchewan, Saskatoon, SK, Canada.

Milan Scheidegger (M)

Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Dimitris Repantis (D)

Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Berlin, Germany.

Classifications MeSH